Professional Diagnostics Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Trends and Insights

Expansion of Molecular and Precision Diagnostics

Molecular diagnostics is becoming a core component of oncology and infectious disease workflows. The FDA approved Guardant360 Liquid CDx in May 2026 as the largest FDA-approved liquid biopsy panel, with a genomic footprint 100 times wider than its predecessor. The platform combines genomic and epigenomic information and includes seven earlier companion diagnostic indications, strengthening treatment selection. Abbott launched its next-generation Oncodetect molecular residual disease test in October 2026, using whole-genome sequencing and MAESTRO technology to track up to 5,000 patient-specific variants. These developments align diagnostic demand with targeted therapy pipelines, which require reliable testing for patient selection and monitoring.

Decentralization of Testing to Professional Point-of-Care Sites

Professional testing is expanding into physician office laboratories, urgent care centers, and specialty clinics as compact systems become more practical for ambulatory care. Roche received FDA clearance and a CLIA waiver for cobas liat CT/NG and CT/NG/MG in 2025, extending molecular sexually transmitted infection testing to point-of-care settings. Truvian's FDA-cleared TruVerus analyzer demonstrated that physician offices can perform common blood tests and obtain results within minutes. This shift can redirect testing volumes from central laboratories without reducing demand for professional-grade testing. Suppliers serving both office-based and central laboratory settings can manage this channel transition more effectively than companies focused on a single testing environment. Product support, result connectivity, staff training, and consistent performance across care settings are becoming increasingly important. Suppliers may also require different commercial offerings, as physician offices prioritize rapid access to defined test menus while central laboratories focus on broader menus, batch efficiency, and automation integration. Clear quality procedures remain essential to ensure confidence in decentralized test results.

Increasing Chronic-Disease Testing Intensity

Chronic disease monitoring generates recurring demand, as patients with diabetes, cardiovascular conditions, and autoimmune disorders require serial testing over extended periods. Immunoassays and clinical chemistry tests support metabolic, endocrine, lipid, kidney function, and cardiac testing. Roche reported a USD 550 million investment in continuous glucose monitoring infrastructure in its 2025 review, highlighting the strategic importance of monitoring. Multimorbidity further increases demand, as patients with multiple conditions often require several test panels during the same clinical encounter. This trend supports reagent demand and provides stable testing volumes for laboratories with broad routine-testing menus. Laboratories must balance routine testing capacity with specialized assay availability for patients with complex care requirements. Broad test menus also enable more consistent utilization of existing instruments across outpatient monitoring and hospital-based care.

Antimicrobial Resistance and Infectious-Disease Surveillance

Antimicrobial resistance surveillance is increasing the demand for diagnostic systems that identify pathogens and support treatment decisions. The World Health Organization's 2025 surveillance report drew on more than 23 million bacteriologically confirmed cases from 110 countries and documented continued resistance in bloodstream and urinary tract infections.^[1] The WHO-backed Global Action Plan calls for expanded diagnostic capacity and improved access to testing for priority pathogens.^[2] The Dx AMR Collaborative launched in Ghana in June 2025 to improve access to rapid multiplex panels and flexible testing options at the primary care level.

Regulatory Complexity and Longer Validation Timelines

The IVDR transition increases validation, documentation, and compliance requirements for suppliers of higher-risk diagnostic products in Europe. Class D devices require European Union Reference Laboratory testing before authorization, while Class C devices have later transition deadlines. Compliance with ISO 15189, GDPR, HIPAA, and IEC 62304 raises costs and extends development timelines, favoring established companies with robust quality systems and regulatory capabilities. Smaller developers may face challenges managing documentation, clinical evidence, and post-market obligations, potentially delaying specialized assay availability.

Reimbursement Pressure and Tender-Based Price Erosion

Tendering and volume-based procurement reduce diagnostic prices in markets where public payers play a major role in laboratory purchasing. QuidelOrtho reported a 33.8% decline in China Labs revenue in local currency in Q3 2026, as customers managed inventory ahead of pricing changes. These conditions can lower returns from high-volume routine assays and instrument placements, prompting suppliers to prioritize oncology, neurology, and rare disease testing, where clinical differentiation can support stronger pricing.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Professional Diagnostics Market Segment Analysis

Instruments and Analyzers held 56.45% of the professional diagnostics market share in 2026, supported by multiyear procurement cycles across hospitals and central laboratories. Reagent-rental and subsidized placement models link instrument access to recurring consumable purchases, increasing the long-term value of installed platforms. Platform validation, staff training, workflow redesign, and clinical integration requirements also create switching barriers for laboratories.

Reagents and Kits are forecast to grow at a 9.28% CAGR through 2032 as molecular, immunoassay, and flow cytometry systems drive repeat testing demand. Roche is expected to introduce 45 new or updated assays in 2025, expanding menu breadth and reagent demand across its installed base. Software and Informatics remains the smallest category, but laboratory system integration, remote monitoring, and digital support increasingly influence analyzer procurement. Biodesix is expected to expand its Bio-Rad partnership in October 2025 to develop and commercialize in vitro diagnostic assays.

Immunoassay held 44.93% of the professional diagnostics market share in 2026, supported by its use in infectious disease serology, hormone testing, cardiac markers, oncology, and autoimmune panels. Central laboratories and near-patient settings rely on these systems for high-volume routine testing. Molecular Diagnostics is forecast to grow at a 10.12% CAGR through 2032 as next-generation sequencing, multiplex panels, and biomarker-guided testing gain wider adoption.

Clinical Chemistry and Hematology remain essential for standardized, high-volume testing and broad patient coverage. Siemens Healthineers is expected to launch the CN-3000 and CN-6000 hemostasis systems in September 2026, combining clotting, chromogenic, immunoassay, and platelet aggregation testing in a platform up to 60% smaller than alternatives. Microbiology, Flow Cytometry, and Urinalysis continue to serve specialized workflows, while automation and data integration improve processing consistency and reduce manual intervention.

Infectious Diseases held 35.67% of the professional diagnostics market size in 2026, driven by respiratory testing, sexually transmitted infection testing, and antimicrobial resistance surveillance. Ongoing antimicrobial resistance in bloodstream and urinary tract infections supports demand for pathogen identification and susceptibility testing. Oncology is forecast to grow at an 11.23% CAGR through 2032 as liquid biopsy, companion diagnostics, and molecular residual disease testing gain wider clinical adoption.

Natera is expected to receive FDA approval for Signatera CDx in muscle-invasive bladder cancer in 2026, supporting circulating tumor DNA use as a treatment-selection biomarker. Diabetes and Metabolic Disorders sustain high testing volumes through HbA1c, lipid, and kidney function testing, while Cardiology relies on hemostasis and coagulation assessment. Roche is expected to launch the Elecsys pTau181 assay in 2025 for Alzheimer's pathology evaluation. Autoimmune and Nephrology testing provide stable recurring demand through repeated laboratory monitoring.

Hospitals and Clinics held 44.34% of the professional diagnostics market share in 2026 due to their need for broad testing menus, large analyzers, and complex laboratory workflows. These facilities remain key users for reference testing, emergency care, oncology, and inpatient monitoring. Physician Office Laboratories are forecast to grow at a 10.45% CAGR through 2032 as CLIA-waived workflows and compact analyzers enable testing closer to patients.

Truvian's FDA-cleared TruVerus system reflects the shift toward office-based blood testing. Diagnostic Laboratories compete on menu breadth, throughput, and turnaround time, while emergency and intensive care settings prioritize rapid results and automated specimen handling. Siemens Healthineers is expected to introduce the Atellica DT 250 Analyzer in September 2025, offering 225 tests per hour and first results in 8 minutes. Suppliers must align instrument design, service, training, and ordering processes with ambulatory care requirements.

Blood and Plasma held 64.45% of the professional diagnostics market size in 2026. These specimens support routine complete blood counts, metabolic panels, and specialized applications such as circulating tumor DNA analysis. Their established collection practices and clinical utility maintain their central role in hospital and laboratory workflows. Saliva and Oral Fluid are forecast to grow at a 7.56% CAGR through 2032 as self-collection and noninvasive sampling gain wider acceptance.

Urine remains important for urinalysis, nephrology testing, and drug-of-abuse programs, while the Atellica DT 250 Analyzer can process urine, serum, and plasma on a single benchtop system. Nasal and Nasopharyngeal Samples remain relevant for respiratory multiplex panels, despite normalized demand from pandemic peaks. rRT-qPCR continues to support respiratory specimen processing. Reliable specimen supply, clear collection protocols, and noninvasive options can expand access, while blood-based testing remains essential for broad analyte measurement and established clinical validation.

Geography Analysis

North America

North America held 41.78% of the professional diagnostics market share in 2026, supported by high testing intensity, established reimbursement pathways, and a large installed base of immunoassay, molecular, and hematology systems. The region remained a key hub for consolidation in cancer screening and precision oncology diagnostics, with Abbott announcing the acquisition of Exact Sciences for USD 23 billion in November 2025 and BD and Waters announcing the combination of BD’s Biosciences and Diagnostic Solutions business with Waters in July 2025. CLIA classifications and FDA 510(k) pathways remained key compliance requirements, while physician office laboratory expansion continued to shift selected testing volumes to ambulatory settings.

Asia-Pacific

Asia-Pacific is forecast to grow at a 9.88% CAGR through 2032, driven by infrastructure investment, a growing middle-income patient population, and broader access to diagnostic services. India is developing cost-competitive diagnostic platforms using microfluidics, biosensors, and AI capabilities, while Sysmex announced a mid-term plan in March 2026 targeting double-digit growth in the Global South and completed the acquisition of JEOL’s BioMajesty clinical chemistry business in April 2026. China’s volume-based procurement model expands testing access but pressures supplier pricing, requiring localized commercial models, product differentiation, and reliable local manufacturing and service capabilities.

Europe, the Middle East and Africa, and South America

Europe is shaped by IVDR requirements, which increase the regulatory burden for manufacturers, while changes to Article 5.5 governance support a more risk-based approach to in-house diagnostics. Gulf states are expanding hospital diagnostic capacity through public health investment, whereas Sub-Saharan Africa relies heavily on infectious disease and antimicrobial resistance programs. In South America, Brazil and Argentina are expanding laboratory networks and government screening programs; however, fragmented registration processes, currency volatility, and tendering pressure create commercial uncertainty. Companies that adapt their test menus and distribution models to local regulatory, funding, and laboratory requirements can better address uneven regional demand.